These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

977 related items for PubMed ID: 25521006

  • 1. Long-term follow-up of dose-adjusted EPOCH plus rituximab (DA-EPOCH-R) in untreated patients with poor prognosis large B-cell lymphoma. A phase II study conducted by the Spanish PETHEMA Group.
    Purroy N, Bergua J, Gallur L, Prieto J, Lopez LA, Sancho JM, García-Marco JA, Castellví J, Montes-Moreno S, Batlle A, de Villambrosia SG, Carnicero F, Ferrando-Lamana L, Piris MA, Lopez A.
    Br J Haematol; 2015 Apr; 169(2):188-98. PubMed ID: 25521006
    [Abstract] [Full Text] [Related]

  • 2. Dose-adjusted EPOCH plus rituximab is an effective regimen in patients with poor-prognostic untreated diffuse large B-cell lymphoma: results from a prospective observational study.
    García-Suárez J, Bañas H, Arribas I, De Miguel D, Pascual T, Burgaleta C.
    Br J Haematol; 2007 Jan; 136(2):276-85. PubMed ID: 17233819
    [Abstract] [Full Text] [Related]

  • 3. Dose-adjusted EPOCH-R (etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin, and rituximab) in untreated aggressive diffuse large B-cell lymphoma with MYC rearrangement: a prospective, multicentre, single-arm phase 2 study.
    Dunleavy K, Fanale MA, Abramson JS, Noy A, Caimi PF, Pittaluga S, Parekh S, Lacasce A, Hayslip JW, Jagadeesh D, Nagpal S, Lechowicz MJ, Gaur R, Lucas A, Melani C, Roschewski M, Steinberg SM, Jaffe ES, Kahl B, Friedberg JW, Little RF, Bartlett NL, Wilson WH.
    Lancet Haematol; 2018 Dec; 5(12):e609-e617. PubMed ID: 30501868
    [Abstract] [Full Text] [Related]

  • 4. Two-weekly dose-adjusted (DA)-EPOCH-like chemotherapy with high-dose dexamethasone plus rituximab (DA-EDOCH14-R) in poor-prognostic untreated diffuse large B-cell lymphoma.
    García-Suárez J, Flores E, Callejas M, Arribas I, Gil-Fernández JJ, Olmedilla G, Curto N, Guillén H, Casco CR, Martín Y, Burgaleta C.
    Br J Haematol; 2013 Feb; 160(4):510-4. PubMed ID: 23228045
    [Abstract] [Full Text] [Related]

  • 5. Intensified chemotherapy with ACVBP plus rituximab versus standard CHOP plus rituximab for the treatment of diffuse large B-cell lymphoma (LNH03-2B): an open-label randomised phase 3 trial.
    Récher C, Coiffier B, Haioun C, Molina TJ, Fermé C, Casasnovas O, Thiéblemont C, Bosly A, Laurent G, Morschhauser F, Ghesquières H, Jardin F, Bologna S, Fruchart C, Corront B, Gabarre J, Bonnet C, Janvier M, Canioni D, Jais JP, Salles G, Tilly H, Groupe d'Etude des Lymphomes de l'Adulte.
    Lancet; 2011 Nov 26; 378(9806):1858-67. PubMed ID: 22118442
    [Abstract] [Full Text] [Related]

  • 6. A single-institution retrospective analysis of outcomes for stage I-II primary mediastinal large B-cell lymphoma treated with immunochemotherapy with or without radiotherapy.
    Binkley MS, Hiniker SM, Wu S, Natkunam Y, Mittra ES, Advani RH, Hoppe RT.
    Leuk Lymphoma; 2016 Nov 26; 57(3):604-8. PubMed ID: 26159046
    [Abstract] [Full Text] [Related]

  • 7. Phase II study of dose-adjusted EPOCH and rituximab in untreated diffuse large B-cell lymphoma with analysis of germinal center and post-germinal center biomarkers.
    Wilson WH, Dunleavy K, Pittaluga S, Hegde U, Grant N, Steinberg SM, Raffeld M, Gutierrez M, Chabner BA, Staudt L, Jaffe ES, Janik JE.
    J Clin Oncol; 2008 Jun 01; 26(16):2717-24. PubMed ID: 18378569
    [Abstract] [Full Text] [Related]

  • 8. R-CHOP versus dose-adjusted R-EPOCH in frontline management of primary mediastinal B-cell lymphoma: a multi-centre analysis.
    Shah NN, Szabo A, Huntington SF, Epperla N, Reddy N, Ganguly S, Vose J, Obiozor C, Faruqi F, Kovach AE, Costa LJ, Xavier AC, Okal R, Kanate AS, Ghosh N, Kharfan-Dabaja MA, Strelec L, Hamadani M, Fenske TS, Calzada O, Cohen JB, Chavez J, Svoboda J.
    Br J Haematol; 2018 Feb 01; 180(4):534-544. PubMed ID: 29265182
    [Abstract] [Full Text] [Related]

  • 9. Gray zone lymphoma with features intermediate between classical Hodgkin lymphoma and diffuse large B-cell lymphoma: characteristics, outcomes, and prognostication among a large multicenter cohort.
    Evens AM, Kanakry JA, Sehn LH, Kritharis A, Feldman T, Kroll A, Gascoyne RD, Abramson JS, Petrich AM, Hernandez-Ilizaliturri FJ, Al-Mansour Z, Adeimy C, Hemminger J, Bartlett NL, Mato A, Caimi PF, Advani RH, Klein AK, Nabhan C, Smith SM, Fabregas JC, Lossos IS, Press OW, Fenske TS, Friedberg JW, Vose JM, Blum KA.
    Am J Hematol; 2015 Sep 01; 90(9):778-83. PubMed ID: 26044261
    [Abstract] [Full Text] [Related]

  • 10. A Cancer and Leukemia Group B multi-center study of DA-EPOCH-rituximab in untreated diffuse large B-cell lymphoma with analysis of outcome by molecular subtype.
    Wilson WH, Jung SH, Porcu P, Hurd D, Johnson J, Martin SE, Czuczman M, Lai R, Said J, Chadburn A, Jones D, Dunleavy K, Canellos G, Zelenetz AD, Cheson BD, Hsi ED, Cancer Leukemia Group B.
    Haematologica; 2012 May 01; 97(5):758-65. PubMed ID: 22133772
    [Abstract] [Full Text] [Related]

  • 11. DA-EPOCH-R improves the outcome over that of R-CHOP regimen for DLBCL patients below 60 years, GCB phenotype, and those with high-risk IPI, but not for double expressor lymphoma.
    Zhang XY, Liang JH, Wang L, Zhu HY, Wu W, Cao L, Fan L, Li JY, Xu W.
    J Cancer Res Clin Oncol; 2019 Jan 01; 145(1):117-127. PubMed ID: 30327941
    [Abstract] [Full Text] [Related]

  • 12. Rituximab combined with MACOP-B or VACOP-B and radiation therapy in primary mediastinal large B-cell lymphoma: a retrospective study.
    Zinzani PL, Stefoni V, Finolezzi E, Brusamolino E, Cabras MG, Chiappella A, Salvi F, Rossi A, Broccoli A, Martelli M.
    Clin Lymphoma Myeloma; 2009 Oct 01; 9(5):381-5. PubMed ID: 19858058
    [Abstract] [Full Text] [Related]

  • 13. [Evaluation of the impact of R-CHOP chemotherapy on efficacy, safety and prognosis in newly diagnosed diffuse large B-cell lymphoma patients and its prognostic impact: a multicenter retrospective study with long term follow-up].
    Cheng ZX, Zou SH, Li F, Li JM, Wang JM, Chen FY, Cao JN, Wang C, Wei Z, Cheng YF.
    Zhonghua Xue Ye Xue Za Zhi; 2012 Apr 01; 33(4):257-60. PubMed ID: 22781712
    [Abstract] [Full Text] [Related]

  • 14. Prognostic significance of MYC, BCL2, and BCL6 rearrangements in patients with diffuse large B-cell lymphoma treated with cyclophosphamide, doxorubicin, vincristine, and prednisone plus rituximab.
    Akyurek N, Uner A, Benekli M, Barista I.
    Cancer; 2012 Sep 01; 118(17):4173-83. PubMed ID: 22213394
    [Abstract] [Full Text] [Related]

  • 15. Outcomes of adults and children with primary mediastinal B-cell lymphoma treated with dose-adjusted EPOCH-R.
    Giulino-Roth L, O'Donohue T, Chen Z, Bartlett NL, LaCasce A, Martin-Doyle W, Barth MJ, Davies K, Blum KA, Christian B, Casulo C, Smith SM, Godfrey J, Termuhlen A, Oberley MJ, Alexander S, Weitzman S, Appel B, Mizukawa B, Svoboda J, Afify Z, Pauly M, Dave H, Gardner R, Stephens DM, Zeitler WA, Forlenza C, Levine J, Williams ME, Sima JL, Bollard CM, Leonard JP.
    Br J Haematol; 2017 Dec 01; 179(5):739-747. PubMed ID: 29082519
    [Abstract] [Full Text] [Related]

  • 16. Attenuated immunochemotherapy regimen (R-miniCHOP) in elderly patients older than 80 years with diffuse large B-cell lymphoma: a multicentre, single-arm, phase 2 trial.
    Peyrade F, Jardin F, Thieblemont C, Thyss A, Emile JF, Castaigne S, Coiffier B, Haioun C, Bologna S, Fitoussi O, Lepeu G, Fruchart C, Bordessoule D, Blanc M, Delarue R, Janvier M, Salles B, André M, Fournier M, Gaulard P, Tilly H, Groupe d'Etude des Lymphomes de l'Adulte (GELA) investigators.
    Lancet Oncol; 2011 May 01; 12(5):460-8. PubMed ID: 21482186
    [Abstract] [Full Text] [Related]

  • 17. Weekly rituximab consolidation following four cycles of R-CHOP induction chemotherapy in very elderly patients with diffuse large B-cell lymphoma: Consortium for improving survival of lymphoma study (CISL).
    Jung SH, Lee JJ, Kim WS, Lee WS, Do YR, Oh SY, Kim MK, Mun YC, Shin HJ, Kwak JY, Kang HJ, Won JH, Kwon JH, Park E, Suh C, Yang DH.
    Eur J Haematol; 2015 Jun 01; 94(6):504-10. PubMed ID: 25288018
    [Abstract] [Full Text] [Related]

  • 18. Activity and safety of dose-adjusted infusional cyclophosphamide, doxorubicin, vincristine, and prednisone chemotherapy with rituximab in very elderly patients with poor-prognostic untreated diffuse large B-cell non-Hodgkin lymphoma.
    Musolino A, Boggiani D, Panebianco M, Vasini G, Salvagni S, Franciosi V, Ardizzoni A.
    Cancer; 2011 Mar 01; 117(5):964-73. PubMed ID: 20960528
    [Abstract] [Full Text] [Related]

  • 19. CHOP-like chemotherapy with or without rituximab in young patients with good-prognosis diffuse large-B-cell lymphoma: 6-year results of an open-label randomised study of the MabThera International Trial (MInT) Group.
    Pfreundschuh M, Kuhnt E, Trümper L, Osterborg A, Trneny M, Shepherd L, Gill DS, Walewski J, Pettengell R, Jaeger U, Zinzani PL, Shpilberg O, Kvaloy S, de Nully Brown P, Stahel R, Milpied N, López-Guillermo A, Poeschel V, Grass S, Loeffler M, Murawski N, MabThera International Trial (MInT) Group.
    Lancet Oncol; 2011 Oct 01; 12(11):1013-22. PubMed ID: 21940214
    [Abstract] [Full Text] [Related]

  • 20. Immunohistochemical double-hit score is a strong predictor of outcome in patients with diffuse large B-cell lymphoma treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone.
    Green TM, Young KH, Visco C, Xu-Monette ZY, Orazi A, Go RS, Nielsen O, Gadeberg OV, Mourits-Andersen T, Frederiksen M, Pedersen LM, Møller MB.
    J Clin Oncol; 2012 Oct 01; 30(28):3460-7. PubMed ID: 22665537
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 49.